China’s SanegeneBio raises $110M in follow-up to metabolic deal with Lilly

Just a month after announcing a deal with Eli Lilly to work on RNAi drugs for metabolic diseases, China’s SanegeneBio has disclosed a $110 million Series B round to fund its …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844